Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: A longitudinal observational study

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Lee, Yvonne C ^a   Cui, Jing ^a   Lu, Bing ^a   Frits, Michelle L ^a   Iannaccone, Christine K ^a   Shadick, Nancy A ^a   Weinblatt, Michael E ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY EUROPEAN LEAGUE AGAINST RHEUMATISM REMISSION CRITERIA; ARTHRALGIA; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; FEMALE; GLOBAL ASSESSMENT SCORE; HUMAN; JOINT SWELLING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE; OBSERVATIONAL STUDY; PREDICTION; QUESTIONNAIRE; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; AGED; CHRONIC PAIN; COHORT ANALYSIS; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN ASSESSMENT; PREVALENCE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRALGIA; ARTHRITIS, RHEUMATOID; CHRONIC PAIN; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PREVALENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 79958070135     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3353     Document Type: Article

References (31)

1. Heiberg T, Finset A, Uhlig T, Kvien TK. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:191-195. 10.1136/ard.2004.022699, 1755377, 15647426.
2. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol 2009, 36:1611-1617. 10.3899/jrheum.080889, 19369454.
3. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, Pazdur J, Bae SC, Palmer W, Xu S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010, 69:1129-1135. 10.1136/ard.2009.116319, 20444749.
4. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908. 10.1002/art.23059, 18050221.
5. Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol 2004, 22:S50-S56.
6. Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005, 52:2616-2624. 10.1002/art.21259, 16142762.
7. Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res 2010, 38:1213-1224.
8. Wolfe F, Michaud K. Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. J Rheumatol 2009, 36:27-33.
9. van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61:704-710. 10.1002/art.24392, 2681785, 19405006.
10. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252-1255.
11. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006, 24:S29-S32.
12. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 2011, 50:40-46.
13. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954-960. 10.1136/ard.2007.084459, 2674547, 18490431.
14. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allart CF, Bathon J, Bombardieri S, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63:573-586. 10.1002/art.30129, 21294106.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
16. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999, 42:2220-2230. 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5, 10524697.
17. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum 1989, 32:37-44. 10.1002/anr.1780320107, 2912463.
18. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009, 146:253-260. 10.1016/j.pain.2009.06.024, 19625125.
19. Wolfe F, Boers M, Felson D, Michaud K, Wells GA. Remission in rheumatoid arthritis: physician and patient perspectives. J Rheumatol 2009, 36:930-933. 10.3899/jrheum.080947, 19332634.
20. Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?. J Rheumatol 2006, 33:1243-1246.
21. Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions?. Clin Exp Rheumatol 2006, 24:S45-S51.
22. Borenstein D, Altman R, Bello A, Chatham W, Clauw DJ, Crofford LJ, Croft J, Hassett A, Kozin F, Pisetsky D, et al. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res (Hoboken) 2010, 62:590-599.
23. Kievit W, Welsing PM, Adang EM, Eijsbouts AM, Krabbe PF, van Riel PL. Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. Arthritis Rheum 2006, 55:745-750. 10.1002/art.22225, 17013821.
24. Pincus T, Sokka T. Can Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases?. Best Pract Res Clin Rheumatol 2007, 21:733-753. 10.1016/j.berh.2007.02.006, 17678833.
25. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004, 31:695-700.
26. Bradley LA, McKendree-Smith NL. Central nervous system mechanisms of pain in fibromyalgia and other musculoskeletal disorders: behavioral and psychologic treatment approaches. Curr Opin Rheumatol 2002, 14:45-51. 10.1097/00002281-200201000-00009, 11790996.
27. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002, 4:299-305. 10.1007/s11926-002-0038-5, 12126581.
28. Wolfe F, Rasker JJ. The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol 2006, 33:2291-2299.
29. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 2005, 64:1410-1413. 10.1136/ard.2005.037333, 1755218, 15941836.
30. Lati C, Guthrie LC, Ward MM. Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis. J Rheumatol 2010, 37:717-722. 10.3899/jrheum.090764, 2959173, 20194445.
31. Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 2007, 34:1475-1479.